At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Mar 9, 2026 at 07:30 ET
Trevi Therapeutics announced positive feedback from its End-of-Phase 2 meeting with the FDA, confirming the development path for Haduvio™ (nalbuphine ER) in IPF-related chronic cough. The company plans to initiate two parallel Phase 3 trials in 2026, marking a significant step toward a potential NDA submission for a condition with no approved therapies.
- FDA alignment achieved on Phase 3 trial design and remaining development program for nalbuphine ER in IPF-related chronic cough
- Two pivotal Phase 3 trials planned: one with ~300 patients (52-week dosing, primary endpoint at 24 weeks), another with ~130 patients (12-week dosing)
- First Phase 3 trial on track to initiate in Q2 2026, second in H2 2026
- Primary endpoint for both trials: relative change in 24-hour cough frequency vs. placebo using objective cough monitoring
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access